By Chris Wack
Lexicon Pharmaceuticals Inc. shares fell 10% to $2.01 after the company reported top-line results of its Phase 2 proof-of-concept study of LX9211 in painful diabetic neuropathy.
The company said LX9211 achieved the primary endpoint of the study, demonstrating a statistically significant reduction in the average daily pain score. Some adverse events were reported at the higher dose, including dizziness, headache and nausea. Nearly all adverse events were reported as mild or moderate.
There were no drug-related serious adverse events reported in the study.
LX9211 is an orally delivered, selective small molecule inhibitor of AAK1, which preclinical studies have shown to reduce pain behavior in models of neuropathic pain without affecting opiate pathways.
LX9211 has received fast track designation from the U.S. Food and Drug Administration for the development in diabetic peripheral neuropathic pain.
Write to Chris Wack at email@example.com
(END) Dow Jones Newswires